Ajinomoto Co., Ltd.

Reverse Proteomics Research Institute Co., Ltd.

Morikazu Kito

Naoyuki Fukuchi

Hiroshi Yamamoto

Yukitsugu Ono

Tsuyoshi Kobayashi

Ryota Yoshimoto

Akira Takahara

Fumie Futaki

Mitsuyo Nagano

Koichi Ishii

Seiji Niwa

Takashi Kayahara

Yorimasa Suwa

Tomoko Takeda

Hajime Koganei

Akiko Tanaka

Seiji Ohno

Yuki Kajigaya

Tadakazu Yamauchi

Naoyuki Yamada

Eiichiro Suzuki

Kohki Ishikawa

Nobuhisa Shimba

Takeshi Tsutsumi

Keiko Gondoh

Hideaki Sueoka

Kouichi Tsuchiya

Katsuhisa Murayama

Kazuo Komiya

Yuko Isono

Takashi Yamamoto

Seiichi Sato

Tomoyuki Onishi

Hiroyuki Matsueda

Munetaka Tokumasu

Yasuko Jojima

Hisayuki Uneyama

Yoko Masuzawa

Shunsuke Kageyama

Masako Hagihara

Akiko Okajima

Junko Shinozaki

Tsuyoshi Yamada

Takayuki Kajiura

Chika Nakanishi

Ken Horiuchi

Akira Nakajo

Motoi Tobita

Hironori Oosaki

The present invention provides novel target proteins and target genes for drug discovery, and the means that enable the development of novel drugs using the same. More particularly, the present invention provides NCS proteins and genes thereof; screening methods for drug (for example, anti-central nervous disease drug); agents for regulating disease (for example, central nervous disease); production methods of a drug derivative; a complex comprising a drug and NCS protein, and a method of producing the complex; a kits comprising a drug or a salt thereof; determination methods for the onset or risk of onset of a specified disease, determination methods for susceptibility to a drug, and determination kits used for the determination methods; and the like.

Drug development target protein and target gene, and method of screening

The present invention provides a novel target protein and a gene for drug discovery, and a means that enables development of a novel pharmaceutical agent by using the same. More particularly, the present invention provides CARP and genes thereof; screening methods for drugs (e.g., antiallergic drugs); a regulator of diseases (e.g., allergic diseases); a drug derivative production method; a complex comprising a drug and CARP, and a production method thereof; kits comprising a drug or a salt thereof; determination methods for the onset or risk of onset of a specified disease, determination methods for susceptibility to a drug, and determination kits used for said methods, and the like.

Target protein and target gene in drug designing and screening method

The present invention provides target proteins and target genes for bioactive substances such as drugs, and means that enable the development of novel bioactive substances using the same. To be specific, the present invention provides target proteins and target genes for bioactive substances; screening methods for substances capable of regulating bioactivities; bioactivity regulators; a bioactive substance derivative production method; a complex comprising a bioactive substance and a target protein, and a method of producing the complex; and kits comprising a bioactive substance or a salt thereof; determination methods for the onset or risk of onset of a specified disease or condition, determination methods for susceptibility to a bioactive substance, and determination kits used for the determination methods, and the like.

A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.

Substance with antithrombotic activity and method for detecting glycokallidin

It is provided a method for producing a subunit peptide originating from an oligomeric protein having disulfide bonds within a subunit and between subunits. The method comprises producing a subunit originating from an oligomeric protein having disulfide bonds within a subunit and between subunits by the following steps:

Process for producing subunit peptide originating in polymer protein

Compounds having a selective N-type calcium channel antagonistic activity are provided. Dihydropyridine derivatives represented by the following formula: analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel, and they are used as therapeutic agents for various diseases relating to N-type calcium channel.

Dihydropyridine derivatives

A method for producing a protein having an antithrombotic activity, which comprises replacing, in a protein that has an amino acid sequence having a homology of not less than 30% to the amino acid sequence of SEQ ID NO: 1 and forms a higher order structure composed of a first &#x3b2; strand (&#x3b2;1), a first a helix (&#x3b1;1), a second &#x3b1; helix (&#x3b1;2), a second &#x3b2; strand (&#x3b2;2), a loop, a third &#x3b2; strand (&#x3b2;3), a fourth &#x3b2; strand (&#x3b2;4) and a fifth &#x3b2; strand (&#x3b2;5) in this order from the amino terminus, at least one amino acid residue in a region from &#x3b1;2 to &#x3b2;2 and/or a region from &#x3b2;3 to &#x3b2;4 so that electric charge of the amino acid residue is changed towards positive direction.

Protein having antithrombotic activity and method for producing the same

Dihydropyrimidine derivatives of the following formula or analogs thereof have selective N-type calcium channel antagonistic activity, and they are used as therapeutic agents for various diseases participating in the N-type calcium channels.

Dihydropyrimidine compounds and compositions containing the same

A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.

Antithrombotic agent and anti-von willebrand factor monoclonal antibody

A method for producing a protein having an antithrombotic activity, which comprises replacing, in a protein that has an amino acid sequence having a homology of not less than 30% to the amino acid sequence of SEQ ID NO: 1 and forms a higher order structure composed of a first &bgr; strand (&bgr;1), a first &agr; helix (&agr;1), a second &agr; helix (&agr;2), a second &bgr; strand (&bgr;2), a loop, a third &bgr; strand (&bgr;3), a fourth &bgr; strand (&bgr;4) and a fifth &bgr; strand (&bgr;5) in this order from the amino terminus, at least one amino acid residue in a region from &agr;2 to &bgr;2 and/or a region from &bgr;3 to &bgr;4 so that electric charge of the amino acid residue is changed towards positive direction.

Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel.

Dihydropyridine derivative

Antithrombotic agent and anti-von Willebrand factor monoclonal antibody

Growing community of inventors

Kawasaki, Japan

Morikazu Kito